Comparative efficacy of switching to natalizumab in active multiple sclerosis

Annals of Clinical and Translational Neurology

Volumn 2, Issue 4, 2015, Pages 373-387

  Spelman, Timothy ^a   Kalincik, Tomas ^a   Zhang, Annie ^b   Pellegrini, Fabio ^c   Wiendl, Heinz ^d   Kappos, Ludwig ^e   Tsvetkova, Larisa ^f   Belachew, Shibeshih ^b   Hyde, Robert ^b   Verheul, Freek ^g   Grand Maison, Francois ^h   Izquierdo, Guillermo ⁱ   Grammond, Pierre ^j   Duquette, Pierre ^k   Lugaresi, Alessandra ^l   Lechner Scott, Jeannette ^m   Oreja Guevara, Celia ⁿ   Hupperts, Raymond ^o   Petersen, Thor ^p   Barnett, Michael ^q   Trojano, Maria ^c   Butzkueven, Helmut ^a,r   more..

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BIOGEN   (United States)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f Biogen Idec Int BV   (Netherlands)

^g GROENE HART HOSPITAL   (Netherlands)

^h HÔPITAL CHARLES LEMOYNE   (Canada)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^j Center de réeadaptation déeficience physique Chaudiéere Appalache   (Canada)

^k Hôpital NotreDame   (Canada)

^l UNIVERSITY OF CHIETI   (Italy)

^m JOHN HUNTER HOSPITAL   (Australia)

ⁿ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^o Zuyderland Medical Centre   (Netherlands)

^p AARHUS UNIVERSITY HOSPITAL   (Denmark)

^q UNIVERSITY OF SYDNEY   (Australia)

^r MONASH UNIVERSITY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84949085892     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/ACN3.180     Document Type: Article

References (38)

1. Caon C, Din M, Ching W, et al. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2006;13:471–474.
2. Coyle PK. Switching algorithms: from one immunomodulatory agent to another. J Neurol 2008;255 (suppl 1):44–50.
3. Carra A, Onaha P, Luetic G, et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. Eur J Neurol 2008;15:386–393.
4. Caon C. Maximising therapeutic outcomes in patients failing on current therapy. J Neurol Sci 2009;277(suppl 1): S33–S36.
5. Panitch H, Goodin D, Francis G, et al. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 2005;239:67–74.
6. Rio J, Tintore M, Sastre-Garriga J, et al. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Eur J Neurol 2012;19:899–904.
7. Gajofatto A, Bacchetti P, Grimes B, et al. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. Mult Scler 2009;15:50–58.
8. Putzki N, Yaldizli O, Maurer M, et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol 2010;17:31–37.
9. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011;10:745–758.
10. Belachew S, Phan-Ba R, Bartholome E, et al. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18:240–245.
11. Butzkueven H, Kappos L, Pellegrini F, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry 2014;85:1190–1197. doi: 10.1136/jnnp-2013-306936.
12. Prosperini L, Gianni C, Leonardi L, et al. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Scler 2012; 18:64–71.
13. Rosenbaum PR, Rubin DB. The central role of propensity scores in observational studies for causal effects. Biometrika 1983;70:41–55.
14. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985;39:33–38.
15. D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265–2281.
16. Kalincik T, Spelman T, Trojano M, et al. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. PLoS One 2013;8:e63480.
17. Butzkueven H, Chapman J, Cristiano E, et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler 2006;12:769–774.
18. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–127.
19. Kalincik T, Buzzard K, Jokubaitis V, et al. Risk of relapse phenotype recurrence in multiple sclerosis. Mult Scler 2014;20:1511–1522. doi: 10.1177/1352458514528762.
20. Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Proceedings of the Twenty-sixth Annual SAS Users group international conference. 2001;26:214–226.
21. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates Publishers, 1988.
22. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083–3107.
23. DiPrete TA, Gangl M. Assessing bias in the estimation of causal effects: Rosenbaum bounds on matching estimators and instrumental variables estimation with imperfect instruments. Sociol Methodol 2004;34:271–310.
24. Keele L. An overview of rbounds: an R package for Rosenbaum bounds sensitivity analysis with matched data. White Paper. Columbus, OH, 2010. p. 1–15.
25. Rosenbaum PR. Observational studies. 2nd ed. New York, NY: Springer, 2002.
26. Rosenbaum PR. “Observational study.” In: Everitt BS, Howell DC, eds. Encyclopedia of statistics in behavioral science. Vol. 3. New York: John Wiley and Sons, 2005. p. 1451–1462.
27. Nannicini T. A simulation-based sensitivity analysis for matching estimators. Stata J 2007;7:334–350.
28. Ichino A, Mealli F, Nannicini T. From temporary help jobs to permanent employment: what can we learn from matching estimators and their sensitivity? J Appl Econ 2008;23:305–327.
29. Liu C, Blumhardt LD. Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves. J Neurol Neurosurg Psychiatry 1999;67:451–456.
30. Liu C, Blumhardt LD. Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability/time curves. The Copolymer 1 Multiple Sclerosis Study Group. J Neurol Sci 2000;181:33–37.
31. Liu C, Blumhardt LD. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts. J Neurol Neurosurg Psychiatry 2000;68:450–457.
32. Yeh ST. Using trapezoidal rule for the area under a curve calculation. NESUG. Collegeville, PA: GlaxoSmithKline, 2002.
33. Tallarida RJ, Murray RB. Manual of pharmacologic calculations with computer programs. New York: Springer-Verlag, 1981.
34. Jolliffe D, Krushelnytskyy B, Semykina A. Censored least absolute deviations estimator: CLAD. Stata Tech Bull 2000;58:13–16.
35. Honore B, Khan S, Powell JL. Quantile regression under random censoring. J Econom 2002;109:67–105.
36. Lanzillo R, Quarantelli M, Bonavita S, et al. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study. Acta Neurol Scand 2012;126:306–314.
37. Kurth T, Walker AM, Glynn RJ, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006;163:262–270.
38. Halpern R, Agarwal S, Borton L, et al. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis. Adv Ther 2011;28:761–775.